Home
Drugs
Palbociclib

Palbociclib

Drug

Drug Profile

Ibrance is the brand name of palbociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It is used in combination endocrine regimens such as aromatase inhibitors or fulvestrant. The FDA first approved Ibrance on February 3, 2015.

Drug Class: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor
Approval Status: FDA approved; first approved February 3, 2015.
Mechanism of Action: Cyclin-dependent kinase 4/6 (CDK4/6) inhibition.

Brand Names

Ibrance

Indications

\HR-positive, HER2-negative advanced or metastatic breast cancer (with aromatase inhibitor or fulvestrant)\

Related News

Oncology Pipeline Update: Prostate Cancer T-Cell Engager Partnership, BTK Inhibitor Filing, and Novel Targeted Therapy Results

Jun 05, 2026

Key oncology developments include a $315 million partnership between Astellas and Vir for the prostate cancer T-cell engager VIR-5500, with updated phase 1 data showing an 82% PSA50 rate. The FDA accepted a filing for Ono Pharmaceuticals' tirabrutinib seeking accelerated approval in primary central nervous system lymphoma. Research findings also identified a new kidney cancer biomarker and showed promising results for the TRK inhibitor repotrectinib and the breast cancer triple therapy gedatolisib plus palbociclib and fulvestrant.

Oncology Drug Market Sees Strong Growth Amid Patent Cliffs and Novel Modality Shifts

Jun 05, 2026

Global oncology drug spending is projected to reach $467 billion by 2030, driven by novel modalities like ADCs and bispecifics, but growth will slow due to patent expirations for key drugs like Keytruda and Lynparza. R&D is shifting, with novel modalities accounting for 33% of clinical trials in 2025. The industry is also seeing broader innovation and investment, with new blockbuster contenders emerging across multiple therapeutic areas.

FDA accepts Genentech application for giredestrant in ESR1-mutated advanced breast cancer

May 19, 2026

The FDA has accepted the New Drug Application for giredestrant plus everolimus in ESR1-mutated, ER-positive, HER2-negative advanced breast cancer. The filing is based on Phase III evERA data showing reduced risk of disease progression or death versus standard-of-care endocrine therapy plus everolimus.

Gedatolisib combinations beat alpelisib regimen in PIK3CA-mutant HR-positive breast cancer

May 05, 2026

Topline phase 3 VIKTORIA-1 results showed gedatolisib combinations improved progression-free survival versus alpelisib plus fulvestrant in PIK3CA-mutant HR-positive/HER2-negative advanced breast cancer. Celcuity plans a supplemental FDA filing based on the data.

SONIA Trial Finds No Overall Survival Benefit for First-Line CDK4/6 Inhibitors in Advanced Breast Cancer

Apr 02, 2026

The SONIA trial found no overall survival benefit for first-line CDK4/6 inhibitors versus second-line use in advanced HR+/HER2- breast cancer. Median survival was 47.9 vs 48.1 months, though post hoc analysis suggested benefit in premenopausal patients. First-line treatment was associated with more severe adverse events.

Phase 3 Breast Cancer Trial Data Highlights from Q1 2026

Apr 01, 2026

Multiple phase 3 breast cancer trials reported significant findings in early 2026, including positive results for novel therapies across different subtypes. Key data includes progression-free survival benefits for palbociclib in HR-positive, HER2-positive advanced breast cancer and investigations of antibody-drug conjugates and combination therapies. Full trial findings are expected to be presented at upcoming medical meetings.

Novartis Acquires Pikavation for Up to $3 Billion in Cancer Pipeline Expansion

Mar 23, 2026

Novartis will acquire Pikavation Therapeutics for up to $3 billion to gain its PI3Kα inhibitor programs, led by SNV4818 for metastatic breast cancer. The deal includes $2 billion upfront and up to $1 billion in milestones, with completion expected in first half 2026. SNV4818 is designed to selectively target mutated PI3Kα while sparing healthy cells.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07492641	BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease	RECRUITING	PHASE3
NCT07405164	Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)	RECRUITING	PHASE3
NCT07347600	A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer	RECRUITING
NCT07191977	Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma	NOT_YET_RECRUITING	PHASE2
NCT07174336	A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)	RECRUITING	PHASE3
NCT07123090	A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma	RECRUITING	PHASE2
NCT06997029	A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors	RECRUITING	PHASE1
NCT06947811	A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations	RECRUITING	PHASE1/PHASE2
NCT06940349	Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors	RECRUITING	PHASE1/PHASE2
NCT06895733	Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)	RECRUITING	PHASE1/PHASE2